ERBB2 and non-small cell lung carcinoma: The median PFS (in months) was 2.1 for EGFR, 3.2 for KRAS, 2.5 for ALK, 3.1 for BRAF, 2.5 for HER2, 2.1 for RET, and 3.4 for MET, suggesting that patients with NSCLC who had actionable tumor alterations poorly responded to immunotherapy, as well as limited efficacy as a single agent5.